Trial Profile
A Phase II Evaluation of Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2-SN-38 Antibody-drug Conjugate, in Patients With Persistent or Recurrent Endometrial Carcinoma
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 21 Mar 2024
Price :
$35
*
At a glance
- Drugs Sacituzumab govitecan (Primary)
- Indications Adenocarcinoma; Carcinoma; Endometrial cancer; Sarcoma; Uterine cancer
- Focus Therapeutic Use
- 15 Mar 2024 Planned primary completion date changed from 1 Feb 2024 to 1 Dec 2024.
- 06 Jun 2023 Results (n=21) of stage 1 of an open-label non-randomized phase 2 trial, presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 23 Mar 2023 Status changed from active, no longer recruiting to recruiting.